

Les publications 2015 du Centre Oscar Lambret

Catégorie A

Adenis, A, Robb, WB, Mariette, C

Esophageal carcinoma.

N. Engl. J. Med. 2015, 372: 1471

IF : 55,873

Rebbeck, TR, Mitra, N, Wan, F, Sinilnikova, OM, Healey, S, McGuffog, L, Peyrat, JP, Hulick, PJ, Andrulis, I

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

JAMA 2015, 313: 1347-61

IF : 35,289

Perez, EA, Awada, A, O'Shaughnessy, J, Rugo, HS, Twelves, C, Im, SA, Mailliez, A, Hannah, AL, Cortes, J

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Lancet Oncol. 2015

IF : 24,69

Mariette, C, Robb, WB, Piessen, G, Adenis, A

Neoadjuvant chemoradiation in oesophageal cancer.

Lancet Oncol. 2015

IF : 24,69

Tabernero, J, Lenz, HJ, Siena, S, Sobrero, A, Falcone, A, Ychou, M, Adenis, A, Grothey, A, Van Cutsem, E

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Lancet Oncol. 2015

IF : 24,69

Blay, JY, Pápai, Z, Tolcher, AW, Italiano, A, Cupissol, D, López-Pousa, A, Penel, N, Le-Guenneq, S, Demetri, GD

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol. 2015, 16: 531-40

IF : 24,69

Pautier, P, Floquet, A, Chevreau, C, Penel, N, Guillemet, C, Delcambre, C, Lacas, B, Duffaud, F

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

Lancet Oncol. 2015, 16: 457-64

IF : 24,69

Melichar, B, Adenis, A, Lockhart, AC, Bennouna, J, Dees, EC, Kayaleh, O, Ullmann, CD, Schusterbauer, C
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.

Lancet Oncol. 2015, 16: 395-405

IF : 24,69

Le Cesne, A, Blay, JY, Domont, J, Tresch-Bruneel, E, Chevreau, C, Bertucci, F, Ryckewaert, T, Clisant, S, Penel, N

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

Lancet Oncol. 2015, 16: 312-9

IF : 24,69

Casali, PG, Le Cesne, A, Poveda Velasco, A, Kotasek, D, Rutkowski, P, Hohenberger, P, Adenis, A, Litière, S, Blay, JY

Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

J. Clin. Oncol. 2015

IF : 18,428

Ray-Coquard, IL, Domont, J, Tresch-Bruneel, E, Bompas, E, Cassier, PA, Mir, O, Clisant, S, Blay, JY, Penel, N
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.

J. Clin. Oncol. 2015

IF : 18,428

Le Péchoux, C, Dunant, A, Faivre-Finn, C, Thomas, PA, Pourel, N, Lerouge, D, Dansin, E, Fadel, E, Zalcmán, G
Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence.

J. Clin. Oncol. 2015

IF : 18,428

Ng, CK, Martelotto, LG, Gauthier, A, Wen, HC, Piscuoglio, S, Lim, RS, Giard, S, Vincent-Salomon, A, Reis-Filho, JS

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Genome Biol. 2015, 16: 107

IF : 10,81

Bellini, A, Bernard, V, Leroy, Q, Rio-Frio, T, Pierron, G, Combaret, V, Defachelles, AS, Delattre, O, Schleiermacher, G

Deep sequencing reveals occurrence of sub-clonal ALK mutations in neuroblastoma at diagnosis.

Clin. Cancer Res. 2015

IF : 8,722

de la Rochefordiere, A, Kamal, M, Floquet, A, Thomas, L, Petrow, P, Petit, T, Maillard, S, Beuzeboc, P, Scholl, SM

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.

Clin. Cancer Res. 2015, 21: 2530-7

IF : 8,722

Besse, B, Le Moulec, S, Mazières, J, Senellart, H, Barlesi, F, Chouaid, C, Dansin, E, Madroszyk, AC, Soria, JC
Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Clin. Cancer Res. 2015, 21: 1896-903

IF : 8,722

Pierga, JY, Petit, T, Lévy, C, Ferrero, JM, Campone, M, Gligorov, J, Bonneterre, J, Bidard, FC, Viens, P
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.

Clin. Cancer Res. 2015, 21: 1298-304

IF : 8,722

Couraud, S, Souquet, PJ, Paris, C, Dô, P, Doubre, H, Pichon, E, Dansin, E, Blanché, H, Zalcman, G
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.

Eur. Respir. J. 2015, 45: 1403-14

IF : 7,636

Gourgou-Bourgade, S, Cameron, D, Poortmans, P, Asselain, B, Azria, D, Cardoso, F, Servent, V, Bellera, C, Dabakuyo-Yonli, TS

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Ann. Oncol. 2015

IF : 7,04

Kramar, A, Negrier, S, Sylvester, R, Joniau, S, Mulders, P, Powles, T, Pasquier, D, Escudier, B, Filleron, T
Guidelines for the definition of time to event endpoints in renal cell cancer clinical trials: results of the DATECAN project.

Ann. Oncol. 2015

IF : 7,04

Bompas, E, Le Cesne, A, Tresch-Bruneel, E, Lebellec, L, Laurence, V, Collard, O, Clisant, S, Penel, N
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).

Ann. Oncol. 2015

IF : 7,04

Toulmonde, M, Le Cesne, A, Piperno-Neumann, S, Penel, N, Chevreau, C, Duffaud, F, Bellera, C, Italiano, A
Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study.

Ann. Oncol. 2015, 26: 1465-70

IF : 7,04

Gourgou-Bourgade, S, Cameron, D, Poortmans, P, Asselain, B, Azria, D, Cardoso, F, Servent, V, Bellera, C, Dabakuyo-Yonli, TS

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Ann. Oncol. 2015, 26: 873-9

IF : 7,04

Bellera, CA, Penel, N, Ouali, M, Bonvalot, S, Casali, PG, Nielsen, OS, Gourgou-Bourgade, S, Mathoulin-Pélissier, S

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Ann. Oncol. 2015, 26: 865-72

IF : 7,04

Tomellini, E, Touil, Y, Lagadec, C, Julien, S, Ostin, P, Ziental-Gelus, N, Meignan, S, Polakowska, R, Le Bourhis, X

Nerve growth factor and proNGF simultaneously promote symmetric self-renewal, quiescence, and epithelial to mesenchymal transition to enlarge the breast cancer stem cell compartment.

Stem Cells 2015, 33: 342-53

IF : 6,523

Brieau, B, Lepère, C, Walter, T, Lecomte, T, Guimbaud, R, Manfredi, S, El Hajbi, F, Rougier, P, Coriat, R

Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues.

Medicine (Baltimore) 2015, 94: e1864

IF : 5,723

Thomas-Teinturier, C, Allodji, RS, Svetlova, E, Frey, MA, Oberlin, O, Millischer, AE, Sudour-Bonnange, H, Lahlou, N, De Vathaire, F

Ovarian reserve after treatment with alkylating agents during childhood.

Hum. Reprod. 2015, 30: 1437-46

IF : 4,569

Lepesant, P, Crinquette, M, Alkeraye, S, Mirabel, X, Dziwniel, V, Cribier, B, Mortier, L

Vismodegib induces significant clinical response in locally advanced trichoblastic carcinoma.

Br. J. Dermatol. 2015

IF : 4,275

Hue-Beauvais, C, Koch, E, Chavatte-Palmer, P, Galio, L, Chat, S, Letheule, M, Révillion, F, Devinoy, E, Charlier, M

Milk from dams fed an obesogenic diet combined with a high-fat/high-sugar diet induces long-term abnormal mammary gland development in the rabbit.

J. Anim. Sci. 2015, 93 : 1641-55

IF : 2,108

Catégorie B

Jiang, X, Pissaloux, D, De La Fouchardiere, C, Desseigne, F, Wang, Q, Attignon, V, Penel, N, Tredan, O, Blay, JY

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Oncotarget 2015

IF : 6,359

Pivot, X, Suter, T, Nabholz, JM, Pierga, JY, Espie, M, Lortholary, A, Kramar, A, Fumoleau, P

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

Eur. J. Cancer 2015

IF : 5,417

Bui-Nguyen, B, Butrynski, JE, Penel, N, Blay, JY, Isambert, N, Milhem, M, Collin, F, van der Graaf, WT

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial.

Eur. J. Cancer 2015, 51: 1312-20

IF : 5,417

Le Cesne, A, Ray-Coquard, I, Duffaud, F, Chevreau, C, Penel, N, Bui Nguyen, B, Cousin, P, Yves Blay, J

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

Eur. J. Cancer 2015, 51: 742-50

IF : 5,417

Taieb, S, Saada-Bouid, E, Tresch, E, Ryckewaert, T, Bompas, E, Italiano, A, Peugniez, C, Clisant, S, Penel, N

Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.

Eur. J. Cancer 2015, 51: 202-9

IF : 5,417

Ben Arush, M, Minard-Colin, V, Mosseri, V, Defachelles, AS, Bergeron, C, Algret, N, Ranchère, D, Orbach, D

Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma?

Eur. J. Cancer 2015, 51: 193-201

IF : 5,417

Faron, M, Pignon, JP, Malka, D, Bourredjem, A, Douillard, JY, Adenis, A, Bouché, O, Ducreux, M

Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.

Eur. J. Cancer 2015, 51: 166-76

IF : 5,417

Hainsworth, JD, Daugaard, G, Lesimple, T, Hübner, G, Greco, FA, Stahl, MJ, Penel, N, Knoblauch, P, Fizazi, KS

Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.

Cancer 2015, 121: 1654-61

IF : 4,889

Kotecki, N, Penel, N, Awada, A

Metabolic disorders associated with the use of targeted cancer therapies.

Curr Opin Oncol 2015, 27: 258-66

IF : 4,466

Leclerc, M, Lartigau, E, Lacornerie, T, Daisne, JF, Kramar, A, Grégoire, V

Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.

Radiother Oncol 2015

IF : 4,363

Moultet-Audouard, R, Lacornerie, T, Tresch, E, Kramar, A, Le Tinier, F, Reynaert, N, Leblanc, E, Narducci, F, Lartigau, E, Nickers, P

What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for cervical cancer?

Radiother Oncol 2015, 115: 386-391

IF : 4,363

Pasquier, D, Barney, B, Sundar, S, Poortmans, P, Villa, S, Nasrallah, H, Zilli, T, Ozsahin, M

Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.

Int. J. Radiat. Oncol. Biol. Phys. 2015, 92: 904-10

IF : 4,258

Jarraya, H, Borde, P, Mirabel, X, Ernst, O, Boulanger, T, Lartigau, E, Ceugnart, L, Kramar, A, Taieb, S

Lobulated enhancement evaluation in the follow-up of liver metastases treated by stereotactic body radiation therapy.

Int. J. Radiat. Oncol. Biol. Phys. 2015, 92: 292-8

IF : 4,258

Lebellec, L, Aubert, S, Zaïri, F, Ryckewaert, T, Chauffert, B, Penel, N

Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses.

Crit. Rev. Oncol. Hematol. 2015, 95: 125-131

IF : 4,027

Bouillet, T, Bigard, X, Bami, C, Chouahnia, K, Copel, L, Dauchy, S, Vanlemmens, L, Zelek, L

Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and Cancer CAMI.

Crit. Rev. Oncol. Hematol. 2015, 94: 74-86

IF : 4,027

Borghesi, Y, Narducci, F, Bresson, L, Tresch, E, Meurant, JP, Cousin, S, Merlot, B, Leblanc, E

Managing Endometrial Cancer: The Role of Pelvic Lymphadenectomy and Secondary Surgery.

Ann. Surg. Oncol. 2015

IF : 3,93

Tunon-de-Lara, C, Chauvet, MP, Baranzelli, MC, Baron, M, Piquenot, J, Le-Bouédec, G, Mathoulin-Pélissier, S, MacGrogan, G

The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study.

Ann. Surg. Oncol. 2015

IF : 3,93

Clough, KB, Acosta-Marín, V, Nos, C, Alran, S, Rouanet, P, Garbay, JR, Giard, S, Rouzier, R, Bonnier, P

Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey.

Ann. Surg. Oncol. 2015

IF : 3,93

Frati, A, Ballester, M, Dubernard, G, Bats, AS, Heitz, D, Mathevet, P, Leblanc, E, Rouzier, R, Daraï, E

Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study.

Ann. Surg. Oncol. 2015, 22: 1980-6

IF : 3,93

Narducci, F, Merlot, B, Bresson, L, Katdare, N, Le Tinier, F, Cordoba, A, Fournier, C, Leblanc, E

Occult invasive cervical cancer found after inadvertent simple hysterectomy: is the ideal management: systematic parametrectomy with or without radiotherapy or radiotherapy only?

Ann. Surg. Oncol. 2015, 22: 1349-52

IF : 3,93

Chastagner, P, Sudour, H, Mriouah, J, Barberi-Heyob, M, Bernier-Chastagner, V, Pinel, S

Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.

Pharm. Res. 2015, 32: 158-66

IF : 3,42

Bibault, JE, Mirabel, X, Lacornerie, T, Tresch, E, Reynaert, N, Lartigau, E

Adapted Prescription Dose for Monte Carlo Algorithm in Lung SBRT: Clinical Outcome on 205 Patients.

PLoS ONE 2015, 10: e0133617

IF : 3,234

Rakotonjanahary, J, De Carli, E, Delion, M, Kalifa, C, Grill, J, Doz, F, Leblond, P, Bertozzi, AI, Rialland, X

Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy.

PLoS ONE 2015, 10: e0127676

IF : 3,234

Catégorie C

Montagne, R, Berbon, M, Doublet, L, Debreuck, N, Baranzelli, A, Drobecq, H, Dansin, E, Furlan, A, Tulasne, D

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences.

Cell Death Dis 2015, 6: e1769

IF : 5,014

Le Rhun, E, Delbeuck, X, Lefeuvre-Plesse, C, Kramar, A, Skrobala, E, Pasquier, F, Bonneterre, J

A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.

Breast Cancer Res. Treat. 2015

IF : 3,94

Bonneterre, J, Hutt, E, Bosq, J, Graham, JD, Powell, MA, Leblanc, E, Zukiwski, AA, Monk, BJ

Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.

Gynecol. Oncol.2015

IF : 3,774

Bats, AS, Frati, A, Mathevet, P, Orliaguet, I, Querleu, D, Zerdoud, S, Leblanc, E, Gauthier, H, Froissart, M, Lecuru, F

Contribution of lymphoscintigraphy to intraoperative sentinel lymph node detection in early cervical cancer: Analysis of the prospective multicenter SENTICOL cohort.

Gynecol. Oncol.2015, 137: 264-9

IF : 3,774

Darai, E, Dubernard, G, Bats, AS, Heitz, D, Mathevet, P, Marret, H, Leblanc, E, Rouzier, R, Ballester, M

Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study.

Gynecol. Oncol.2015, 136: 54-9

IF : 3,774

Falk, AT, Moureau-Zabotto, L, Ouali, M, Penel, N, Italiano, A, Bay, JO, Thyss, A, Thariat, J

Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group.

Clin Oncol (R Coll Radiol) 2015, 27: 48-55

IF : 3,398

Penel-Page, M, Ray-Coquard, I, Larcade, J, Girodet, M, Bouclier, L, Rogasik, M, Lervat, C, Blay, JY, Marec-Bérard, P

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

BMC Cancer 2015, 15: 854

IF : 3,362

Khalifa, J, Ouali, M, Chaltiel, L, Le Guellec, S, Le Cesne, A, Blay, JY, Penel, N, Chevreau, C

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

BMC Cancer 2015, 15: 700

IF : 3,362

Ligier, K, Maynou, C, Leroy, X, Robin, YM, Martin, P, Clisant, S, Richard, F, Penel, N

Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study.

BMC Cancer 2015, 15: 218

IF : 3,362

Brodowicz, T, Liegl-Atzwager, B, Tresch, E, Taieb, S, Kramar, A, Gruenwald, V, Vanseymortier, M, Clisant, S, Le Cesne, A, Penel, N

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.

BMC Cancer 2015, 15: 127

IF : 3,362

Zairi, F, Le Rhun, E, Bertrand, N, Boulanger, T, Taillibert, S, Aboukais, R, Assaker, R, Chamberlain, MC

Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients.

J. Neurooncol. 2015

IF : 3,07

Hochart, A, Gaillard, V, Baroncini, M, André, N, Vannier, JP, Vinchon, M, Sudour Bonnange, H, Bonne, NX, Leblond, P

Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

J. Neurooncol. 2015

IF : 3,07

Refaat, T, Castelain, B, Small, W, Elsaïd, A, Lotfy, N, Lartigau, E, Nickers, P

Concomitant Chemoradiotherapy With Image-guided Pulsed Dose Rate Brachytherapy as a Definitive Treatment Modality for Early-stage Cervical Cancer.

Am. J. Clin. Oncol. 2015, 38: 289-93

IF : 3,062

Denost, Q, Faucheron, JL, Lefevre, JH, Panis, Y, Cotte, E, Rouanet, P, Jafari, M, Capdepont, M, Rullier, E

French current management and oncological results of locally recurrent rectal cancer.

Eur J Surg Oncol 2015

IF : 3,009

Ferron, G, Simon, L, Guyon, F, Glehen, O, Goere, D, Elias, D, Leblanc, E, Herin, F, Villeneuve, L

Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey.

Eur J Surg Oncol 2015

IF : 3,009

Lepage, C, Phelip, JM, Cany, L, Faroux, R, Manfredi, S, Ain, JF, Adenis, A, Bedenne, L, Bouché, O

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

Dig Liver Dis 2015, 47: 529-31

IF : 2,963

Bachet, JB, Gay, F, Maréchal, R, Galais, MP, Adenis, A, MsC, DS, Godfrin, Y, André, T

Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.

Pancreas 2015, 44: 1141-7

IF : 2,959

Lefebvre-Kuntz, D, Dualé, C, Albi-Feldzer, A, Nougarède, B, Falewee, MN, Ouchchane, L, Dubray, C, Schoeffler, P

General anaesthetic agents do not influence persistent pain after breast cancer surgery: A prospective nationwide cohort study.

Eur J Anaesthesiol, 2015

IF : 2,942

Ducassou, A, Gambart, M, Munzer, C, Padovani, L, Carrie, C, Haas-Kogan, D, Defachelles, AS, Munzer, M, Laprie, A

Long-term side effects of radiotherapy for pediatric localized neuroblastoma : Results from clinical trials NB90 and NB94.

Strahlenther Onkol 2015, 191: 604-612

IF : 2,914

Rahier, NJ, Molinier, N, Long, C, Deshmukh, SK, Kate, AS, Ranadive, P, Meignan, S, Sautel, F, Bailly, C

Anticancer activity of kojic acid and semisynthetic derivatives.

Bioorg. Med. Chem. 2015, 23: 3712-21

IF : 2,793

Chastagner, P, Devictor, B, Geoerger, B, Aerts, I, Leblond, P, Frappaz, D, Bracard, S, André, N

Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.

Cancer Chemother. Pharmacol. 2015

IF : 2,769

Krebs, L, Maillard, S, Gaillot-Petit, N, Ortholan, C, Nguyen, TD

Total radiation dose and overall treatment time are predictive for tumor sterilization in cervical carcinoma treated with chemoradiation and pulsed-dose-rate brachytherapy.

Brachytherapy 2015, 14: 16-22

IF : 2,758

Boydev, C, Taleb-Ahmed, A, Derraz, F, Peyrodie, L, Thiran, JP, Pasquier, D

Development of CBCT-based prostate setup correction strategies and impact of rectal distension.

Radiat Oncol 2015, 10: 83

IF : 2,546

Arsène, E, Bleu, G, Merlot, B, Boulanger, L, Vinatier, D, Kerdraon, O, Collinet, P

Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer.

J Gynecol Oncol 2015, 26: 125-33

IF : 2,494

Malric, A, Defachelles, AS, Leblanc, T, Lescoeur, B, Lacour, B, Peuchmaur, M, Stoppa-Lyonnet, D, Bourdeaut, F

Fanconi anemia and solid malignancies in childhood: a national retrospective study.

Pediatr Blood Cancer 2015, 62: 463-70

IF : 2,386

Christophe, V, Duprez, C, Congard, A, Antoine, P, Lesur, A, Fournier, E, Vanlemmens, L

The subjective experience of young women with non-metastatic breast cancer: the Young Women with Breast Cancer Inventory.

Health Qual Life Outcomes 2015, 13: 73

IF : 2,12

Cabarrou, B, Jouin, A, Boher, JM, Kramar, A, Filleron, T

Assessment of health status over time by Prevalence and Weighted Prevalence functions: Interface in R. Comput Methods Programs Biomed 2015, 118: 298-308

IF : 1,897

Coevoet, E, Reynaert, N, Lartigau, E, Schiappacasse, L, Dequidt, J, Duriez, C

Registration by interactive inverse simulation: application for adaptive radiotherapy.

Int J Comput Assist Radiol Surg 2015

IF : 1,707

Catégorie D

Leroy, T, Fournier, E, Penel, N, Christophe, V

Crossed views of burden and emotional distress of cancer patients and family caregivers during palliative care.

Psychooncology 2015

IF : 2,443

Sorin, T, Fyad, JP, Delay, E, Rouanet, P, Rimareix, F, Houpeau, JL, Verhaeghe, JL, Marchal, F

Occult cancer in specimens of reduction mammoplasty aimed at symmetrization. A multicentric study of 2718 patients.

Breast 2015, 24: 272-7

IF : 2,381

Hochart, A, Dieux, A, Coucke, P, Fron, D, Fayoux, P, Labalette, P, Rocourt, N, Vinchon, M, Leblond, P

Association between kniest dysplasia and chondrosarcoma in a child.

Am. J. Med. Genet. A 2015

IF : 2,159

Narducci, F, Lambaudie, E, Mautone, D, Hudry, D, Bresson, L, Leblanc, E

Extraperitoneal Para-aortic Lymphadenectomy by Robot-Assisted Laparoscopy in Gynecologic Oncology: Preliminary Experience and Advantages and Limitations.

Int. J. Gynecol. Cancer 2015

IF : 1,958

Marino, P, Houvenaeghel, G, Narducci, F, Boyer-Chammard, A, Ferron, G, Uzan, C, Perez, T, Lambaudie, E

Cost-Effectiveness of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications.

Int. J. Gynecol. Cancer 2015, 25: 1102-8

IF : 1,958

Garabedian, C, Merlot, B, Bresson, L, Tresch, E, Narducci, F, Leblanc, E

Minimally invasive surgical management of early-stage cervical cancer: an analysis of the risk factors of surgical complications and of oncologic outcomes.

Int. J. Gynecol. Cancer 2015, 25: 714-21

IF : 1,958

Hudry, D, Ahmad, S, Zanagnolo, V, Narducci, F, Fastrez, M, Ponce, J, Holloway, RW, Lambaudie, E

Robotically assisted para-aortic lymphadenectomy: surgical results: a cohort study of 487 patients.

Int. J. Gynecol. Cancer 2015, 25: 504-11

IF : 1,958

Franké, O, Narducci, F, Chereau-Ewald, E, Orsoni, M, Jauffret, C, Leblanc, E, Houvenaeghel, G, Lambaudie, E

Role of a double docking to improve lymph node dissection: when robotically assisted laparoscopy for para-aortic lymphadenectomy is associated to a pelvic procedure.

Int. J. Gynecol. Cancer 2015, 25: 331-6

IF : 1,958

Bats, AS, Frati, A, Froissart, M, Orliaguet, I, Querleu, D, Zerdoud, S, Leblanc, E, Gauthier, H, Mathevet, P, Lecuru, F

Feasibility and performance of lymphoscintigraphy in sentinel lymph node biopsy for early cervical cancer: results of the prospective multicenter SENTICOL study.

Ann Nucl Med 2015, 29: 63-70

IF : 1,677

Sudour-Bonnange, H, Rocourt, N, Aubry, E, Lervat, C, Kerdraon, O

A Sex Cord-stromal Tumor, Specifically a Fibroma, Arising From the Uterine Corpus: A Case Report.

Int. J. Gynecol. Pathol. 2015

IF : 1,665

Christophe, V, Duprez, C, Congard, A, Fournier, E, Lesur, A, Antoine, P, Vanlemmens, L

Evaluate the subjective experience of the disease and its treatment in the partners of young women with non-metastatic breast cancer.

Eur J Cancer Care (Engl) 2015

IF : 1,564

Levêque, C, Vayssière, C, Favre, R, Audibert, F, Chauvet, MP, Maillard, F, Elhinger, V, Arnaud, C

Cervical length in asymptomatic twin pregnancies: prospective multicenter comparison of predictive indicators.

J. Matern. Fetal. Neonatal. Med. 2015, 28: 37-40

IF : 1,367

Szymanski, C, Bourgault, C, Penel, N, Maynou, C

Chondrosarcoma of the femur in Mazabraud's syndrome: A first case study.

Orthop Traumatol Surg Res 2015

IF : 1,256

Reich, M

[Psychiatric disorders in palliative care and at the end of life].

Presse Med 2015, 44: 442-55

IF : 1,077

Chalavon, E, Lampin, ME, Lervat, C, Leroy, X, Bonneville, M, Recher, M, Sudour-Bonnange, H

Dilated Cardiomyopathy Caused by Wilms Tumor.

Pediatr Emerg Care 2015

IF : 1,046

Catégorie E

Bibault, JE, Oudoux, A, Durand-Labrunie, J, Mirabel, X, Lartigau, É, Kolesnikov-Gauthier, H

[Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation].

Cancer Radiother 2015

IF : 1,411

Taillibert, S, Conforti, R, Bonneterre, J, Bachelot, T, Le Rhun, E, Bernard-Marty, C

[Systemic treatment of brain metastases from breast cancer].

Cancer Radiother 2015, 19 : 36-42

IF : 1,411

Delmaire, C, Savatovsky, J, Boulanger, T, Dhermain, F, Le Rhun, E, Météllus, P, Carsin-Nicole, B, Petyt, G

[Brain metastases imaging].

Cancer Radiother 2015, 19: 16-9

IF : 1,411

Demol, B, Viard, R, Reynaert, N

Monte Carlo calculation based on hydrogen composition of the tissue for MV photon radiotherapy. J Appl Clin Med Phys 2015, 16: 5586

IF : 1,172

Delebarre, M, Garnier, N, Macher, E, Thebaud, E, Mazingue, F, Leblond, P, Martinot, A, Dubos, F

Which Variables Are Useful for Predicting Severe Infection in Children With Febrile Neutropenia? J. Pediatr. Hematol. Oncol. 2015, 37: e468-74

IF : 0,902

Sudour-Bonnange, H, Leblond, P, Cellier, C, Vinchon, M, Lervat, C, Rocourt, N, Schleiermacher, G

Bone Vertebrae Metastases With Spinal Cord Compression: A Rare Event in Wilms Tumor.

J. Pediatr. Hematol. Oncol. 2015, 37: e387-9

IF : 0,902

Levy, G, Bonneville, M, Rocourt, N, Sudour, H, Defachelles, AS

Necrotizing enterocolitis as an adverse effect of recombinant interleukin-2 and Ch14.18 in maintenance therapy for high-risk neuroblastoma.

J. Pediatr. Hematol. Oncol. 2015, 37: e250-2

IF : 0,902

Cortet-Rudelli, C, Bonneville, JF, Borson-Chazot, F, Clavier, L, Coche Dequéant, B, Desaillood, R, Toussaint, P, Chanson, P

Post-surgical management of non-functioning pituitary adenoma.

Ann. Endocrinol. (Paris) 2015

IF : 0,871

Azaïs, H, Bresson, L, Bassil, A, Katdare, N, Merlot, B, Houpeau, JL, Tresch, E, Narducci, F

Chemotherapy drug extravasation in totally implantable venous access port systems: how effective is early surgical lavage?

J Vasc Access 2015, 16: 31-7

IF : 0,846

Dansin, E, Lauridant, G, Reich, M, Villet, S, Fournel, P

[Reflections on the limits of specific treatments in thoracic oncology].

Rev Mal Respir 2015, 32: 166-72

IF : 0,62

Reich, M, Clermont, A, Amela, É, Kotecki, N

[Factitious diseases in oncology].

Bull Cancer 2015

IF : 0,604

Danklou, J, Strobbe, G, Delbey, S, Lefebvre-Kuntz, D, Marliot, G

[Prevalence, indication and compliance with the recommendations of prescription of low molecular weight heparin in oncology].

Bull Cancer 2015

IF : 0,604

Gamblin, V, Da Silva, A, Villet, S, El Hajbi, F

[Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].

Bull Cancer 2015

IF : 0,604

Penel, N, Cousin, S, Kotecki, N

[Soft tissue sarcomas: Questions about reported clinical benefit].

Bull Cancer 2015

IF : 0,604

Fournier, E, Fournier, C, Christophe, V, Reich, M, Villet, S, Gamblin, V, Ryckewaert, T, Clisant, S, Antoine, P, Penel, N

Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases.

Bull Cancer 2015

IF : 0,604

Luporsi, E, Bellocq, JP, Barrière, J, Bonastre, J, Chetritt, J, Le Corroller, AG, Peyrat, JP, Mazeau-Woynar, V, Kassab-Chahmi, D

[uPA/PAI-1, Oncotype DX™, MammaPrint®). Prognosis and predictive values for clinical utility in breast cancer management].

Bull Cancer 2015

IF : 0,604

Penel, N, Ryckewaert, T, Amela, EY

[Docetaxel and prostate cancer: Early but not too early].

Bull Cancer 2015

IF : 0,604

Berger, C, El Fayeche, C, Pacquement, H, Demoor-Goldschmidt, C, Ducassou, S, Ansoberlo, S, Defachelles, AS

[Objectives and organization for the long-term follow-up after childhood cancer].

Bull Cancer 2015, 102: 579-85

IF : 0,604

Morice, P, Uzan, C, Gouy, S, Bentivegna, E, Leblanc, E, Chabbert-Buffet, N, Darai, E

[Fertility preservation in oncology: Updates in 2015].

Bull Cancer 2015, 102: 399-400

IF : 0,604

Heudel, PE, Selle, F, Morice, P, Rouzier, R, Taieb, S, Devouassoux-Shisheboran, M, Balleyguier, C, Ray-Coquard, I

[Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?]

Bull Cancer 2015

IF : 0,604

Sudour-Bonnange, H, Vanrenterghem, A, Nobili, F, Guignonis, V, Boudailliez, B

[Renal late effects in patients treated for cancer in childhood].

Bull Cancer 2015, 102: 627-35

IF : 0,604

Vanlerenberghe, E, Sedda, AL, Ait-Kaci, F

[The impact of gynaecological cancers on woman's sexuality and her couple].

Bull Cancer 2015, 102: 454-462

IF : 0,604

Rigaux, P, Lefebvre-Kuntz, D, Penel, N

Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid.

Bull Cancer 2015, 102: 213-6

IF : 0,604

Ezzalfani, M, Dugué, A, Mollevi, C, Pulido, M, Bonnetain, F, Filleron, T, Kramar, A, Paoletti, X

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Bull Cancer 2015, 102: 73-82

IF : 0,604

Jauffret, C, Houvenaeghel, G, Classe, JM, Garbay, JR, Giard, S, Charitansky, H, Chauvet, MP, Goncalves, A, Lambaudie, É

[Lobular invasive breast cancer prognostic factors: About 940 patients].

Gynecol Obstet Fertil 2015

IF : 0,522

Cheurfa, N, Giard, S

[Non-palpable breast cancer malignant on needle core biopsy and no malignancy in surgical excision: how to manage?].

Gynecol Obstet Fertil 2015, 43: 18-24

IF : 0,522

Cremer, R, Lervat, C, Laffargue, A, Le Cunff, J, Joriot, S, Minnaert, C, Storme, L, Vandoolaeghe, S

[Organization of collaborative deliberation for limiting or withholding treatments in children].

Arch Pediatr 2015

IF : 0,407

Catégorie NC

Balossier, A, Blond, S, Touzet, G, Sarrazin, T, Lartigau, E, Reyns, N

Role of radiosurgery in the management of pineal region tumours: indications, method, outcome. *Neurochirurgie* 2015, 61: 216-22

IF : 0,406

Azria, D, Riou, O, Castan, F, Nguyen, TD, Peignaux, K, Lemanski, C, Kramar, A, Fenoglietto, P, Ozsahin, EM

Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial.

EBioMedicine 2015, 2: 1965-73

Cordoba, A, Nickers, P, Tresch, E, Castelain, B, Leblanc, E, Narducci, F, Le Tinier, F, Lesoin, A, Lacornerie, T, Lartigau, E

Safety of adjuvant intensity-modulated postoperative radiation therapy in endometrial cancer: Clinical data and dosimetric parameters according to the International Commission on Radiation Units (ICRU) 83 report. *Rep Pract Oncol Radiother* 2015, 20: 385-92

Nguyen, T, Levy, G, Poncelet, E, Le Thanh, T, Prolongeau, JF, Phalippou, J, Massoni, F, Laurent, N

Overview of digital breast tomosynthesis: Clinical cases, benefits and disadvantages.

Diagn Interv Imaging 2015

Dumont, A, Pannier, D, Ducoulombier, A, Tresch, E, Chen, J, Kramar, A, Révillion, F, Peyrat, JP, Bonneterre, J

ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.

Springerplus 2015, 4: 327

Hochart, A, Escande, F, Rocourt, N, Grill, J, Koubi-Pick, V, Beaujot, J, Meignan, S, Maurage, CA, Leblond, P

Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma.

Ann Clin Transl Neurol 2015, 2: 439-43

Dansin, E, Carnot, A, Servent, V, Daussay, D, Robin, YM, Surmei-Pintilie, E, Lauridant, G, Révillion, F, Delattre, C

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report.

Case Rep Oncol 2015, 8: 164-8

Le Rhun, E, Taillibert, S, Boulanger, T, Zairi, F, Bonneterre, J, Chamberlain, MC

Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.

Case Rep Oncol 2015, 8: 72-7

Garreau, É, Wojcik, T, Rakotomalala, H, Raoul, G, Ferri, J

Symphyseal distraction in the context of orthodontic treatment: a series of 35 cases.

Int Orthod 2015, 13: 81-95

Daghfous, A, Toledano, E, Kalsoum, E, Tempremant, F, Boulanger, T, Leclerc, X, Pruvo, JP

Fabry disease.

Diagn Interv Imaging 2015, 96: 307-9

Participation de médecins du Centre Oscar Lambret aux publications suivantes :

Mayer, RJ, Van Cutsem, E, Falcone, A, Yoshino, T, Garcia-Carbonero, R, Mizunuma, N, Ito, M, Ohtsu, A
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

N. Engl. J. Med. 2015, 372: 1909-19

IF : 55,873

Garon, EB, Rizvi, NA, Hui, R, Leighl, N, Balmanoukian, AS, Eder, JP, Emancipator, K, Gandhi, L
Pembrolizumab for the treatment of non-small-cell lung cancer.

N. Engl. J. Med. 2015, 372: 2018-28

IF : 55,873

Dowsett, M, Forbes, JF, Bradley, R, Ingle, J, Aihara, T, Bliss, J, Davies, C, Gray, R

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Lancet 2015, 386: 1341-52

IF : 45,217

Pritchard-Jones, K, Bergeron, C, de Camargo, B, van den Heuvel-Eibrink, MM, Acha, T, Godzinski, J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group.

Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.

Lancet 2015, 386: 1156-64

IF : 45,217

Kuchenbaecker, KB, Ramus, SJ, Tyrer, J, Lee, A, Shen, HC, Beesley, J, Antoniou, AC, Chenevix-Trench, G

Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

Nat. Genet 2015, 47: 164-71

IF : 29,352

Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulas V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Lancet Oncol. 2015, 16: 897-907

IF : 24,69

Thatcher, N, Hirsch, FR, Luft, AV, Szczesna, A, Ciuleanu, TE, Dediu, M, Paz-Ares, L, Socinski, MA

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Lancet Oncol. 2015, 16: 763-74

IF : 24,69

Couraud, S, Debieuvre, D, Moreau, L, Dumont, P, Margery, J, Quoix, E, Zalcman, G, Souquet, PJ
No impact of passive smoke on the somatic profile of lung cancers in never-smokers.

Eur. Respir. J. 2015, 45: 1415-25

IF : 7,636

Croce, S, Ribeiro, A, Brulard, C, Noel, JC, Amant, F, Stoeckle, E, Farre, I, MacGrogan, GM, Chibon, F
Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Mod. Pathol. 2015, 28: 1001-10

IF : 6,187

Rondeau, V, Pignon, JP, Michiels, S

A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer.

Stat Methods Med Res 2015, 24: 711-29

IF : 4,472

van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group.

Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.

Eur. J. Cancer 2015, 51: 2453-64

IF : 5,417

Vincent J, Mariette C, Pezet D, Huet E, Bonnetain F, Bouché O, Conroy T, Rouillet B, Seitz JF, Herr JP, Di Fiore F, Jouve JL, Bedenne L; Fédération Francophone de Cancérologie Digestive (FFCD).

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

Eur. J. Cancer 2015, 51: 1683-93

IF : 5,417

Blanco, I, Kuchenbaecker, K, Cuadras, D, Wang, X, Barrowdale, D, de Garibay, GR, Antoniou, AC, Pujana, MA

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.

PLoS ONE 2015, 10 : e0120020

IF : 3,234

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO).

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Target Oncol 2015, 10: 583-96

IF : 4

Damiola F, Schultz I, Barjhoux L, Sornin V, Dondon MG, Eon-Marchais S, Marcou M; GENESIS Study Investigators, Caron O, Gauthier-Villars M, de Pauw A, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard C, Pujol P, Lasset C, Longy M, Bignon YJ, Fricker JP, Andrieu N, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Muller D.

Mutation analysis of PALB2 gene in French breast cancer families.

Breast Cancer Res. Treat. 2015, 154: 463-71

IF : 3,94

Gauthé, M, Richard-Molard, M, Cacheux, W, Michel, P, Jouve, JL, Mitry, E, Alberini, JL, Lièvre, A

Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.

Dig Liver Dis 2015, 47: 443-454

IF : 2,963

Beaujot, J, Leteurtre, E, Do Cao, C, Beron, A, Caiazzo, R, Vantighem, MC

Potential role of parasitosis in tumorigenesis: case study of heart metastasis as the only presenting symptom of an ileal neuroendocrine tumor.

Presse Med 2015, 44: 102-6

IF : 1,077